Whalesbook
Novo Nordisk AG is implementing significant price reductions for its blockbuster diabetes and weight-loss treatments, Ozempic and Wegovy, in India. This strategic move comes after the patent for semaglutide, the active ingredient, expired, allowing major Indian pharmaceutical firms like Sun Pharma, Zydus Lifesciences, and Dr. Reddy's Laboratories to launch more affordable generic versions.
Price Cuts Target Price-Sensitive Market
Novo Nordisk has already cut the price of Ozempic by 36% and the starting dose of Wegovy by 48% in India. Executive Vice-President Emil Larsen stated that remaining competitive in India's price-sensitive market, where demand for weight-loss drugs is still developing, is crucial.
Leveraging Brand Trust and Partnerships
Larsen acknowledged the crowded market but stressed Novo Nordisk's goal to maintain competitiveness by emphasizing its product quality and established brand recognition. He pointed to the company's long success with insulin products, even after patent expiries, thanks to its brand name and quality assurance. Novo Nordisk has also formed local partnerships, including agreements with Emcure Pharma Ltd. for the 'Poviztra' injection and with Abbott India Ltd. for 'Extensior,' leveraging their extensive distribution networks.
Market Size Remains a Key Hurdle
Despite the influx of generics, Larsen identified the limited size of India's weight-loss drug market as a key challenge and opportunity. He noted that Novo Nordisk treats more patients in Denmark than in India, highlighting growth potential as awareness and accessibility increase. The company believes a strong, quality brand with a history of good outcomes, offered at a reasonable price, can be highly effective in emerging markets.